Q3 2020 Form 10-Q Summary
Entity note: The supplied filing is for Homology Medicines, Inc. (Nasdaq: FIXX), not Q32 Bio Inc. It covers the quarter and nine months ended September 30, 2020; the financial statements are unaudited.
Business context
Homology is a clinical-stage genetic medicines company developing gene therapy and nuclease-free gene-editing treatments for rare genetic diseases. It had no approved products and no product-sale revenue. Its lead clinical program, HMI-102, is being studied for phenylketonuria (PKU).
Financial results and liquidity
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Collaboration revenue | $0.6 million | $0.4 million | $1.7 million | $1.1 million |
| Research and development | $20.4 million | $25.7 million | $77.2 million | $69.1 million |
| General and administrative | $8.4 million | $6.0 million | $25.0 million | $16.4 million |
| Total operating expenses | $28.8 million | $31.7 million | $102.2 million | $85.5 million |
| Net loss | $28.2 million | $29.6 million | $98.9 million | $79.7 million |
| Basic and diluted loss per share | $0.62 | $0.67 | $2.19 | $1.92 |
- At September 30, cash and cash equivalents were $178.0 million; restricted cash was $1.3 million. There were no short-term investments on the balance sheet, versus $208.6 million at year-end 2019.
- Operating cash use for the first nine months was $82.7 million, compared with $65.0 million a year earlier. Investing activities provided $205.9 million, largely reflecting maturities of short-term investments; financing activities provided $1.1 million.
- Total assets were $228.4 million and stockholders’ equity was $170.2 million. The company reported no debt. Current liabilities were $17.2 million against current assets of $181.3 million.
- No product gross margin was reported because the company had no product sales. Collaboration revenue is recognized over time and is not expected to be even across periods.
Changes and notable developments
- For Q3, net loss narrowed by $1.4 million year over year, mainly as R&D expense fell by $5.3 million, partly offset by higher G&A and sharply lower interest income.
- For the first nine months, net loss increased by $19.2 million year over year as R&D and G&A costs rose; interest income also declined. Higher development spending reflected advancement of multiple programs and increased staffing, partly offset by lower early-stage research costs.
- HMI-102 trial updates reported six patients across three dose cohorts. The two lowest-dose patients showed no meaningful reduction in phenylalanine. In the mid- and high-dose cohorts, one patient in each showed a marked reduction; the other patients did not show similar reductions and had pre-existing immune conditions and Grade 3 ALT elevations. The company said these preliminary findings require further evaluation.
- Management planned to begin the randomized expansion phase of the HMI-102 trial in early 2021, using two selected doses. HMI-202 and HMI-103 were in later-stage IND-enabling work; HMI-203, a Hunter syndrome program announced in October 2020, had entered IND-enabling studies.
- In a November 9, 2020 agreement, Pfizer agreed to buy 5.0 million shares for $60 million ($12 per share), subject to customary closing conditions. Pfizer also received a 30-month right of first refusal to negotiate potential collaborations on HMI-102 and HMI-103. The filing’s cash runway estimate assumes receipt of these proceeds.
Outlook, risks and contingencies
- Management estimated that existing cash and the anticipated Pfizer proceeds would fund projected operations into Q3 2022. This is an estimate based on assumptions; the company said it may use cash sooner and may need further financing.
- Management expected operating expenses and capital expenditures to increase as clinical and preclinical programs advance, manufacturing scales, and the company expands its workforce and intellectual-property portfolio.
- COVID-19 had caused or could cause delays in clinical-trial enrollment and disruptions to research, suppliers, manufacturing, and regulatory interactions. The company reported mitigation measures, including remote patient services and advance procurement of raw materials.
- Key risks include continued losses, dependence on additional capital and HMI-102, uncertain clinical and regulatory outcomes, potential treatment-related adverse events, manufacturing and supply constraints, collaboration dependence, and intellectual-property challenges.
- Novartis collaboration deferred revenue was $30.4 million at September 30, 2020. The company was eligible for up to $265 million in specified development, regulatory, and commercial milestones, plus tiered royalties; these amounts were contingent and not included in the recognized transaction price.
- The filing reported no material legal proceedings, no off-balance-sheet arrangements, and no material changes in contractual obligations. Management concluded disclosure controls were effective as of September 30, 2020.
Important facts for investors to verify
- Confirm the issuer: this filing is Homology Medicines, Inc., not Q32 Bio Inc.
- Track HMI-102’s full trial data, safety findings, dose selection, enrollment, and timing of the planned expansion phase; the cited patient data were preliminary.
- Verify closing and receipt of the $60 million Pfizer investment and understand the right-of-first-refusal terms and potential implications for partnering.
- Assess cash burn and runway against actual development, manufacturing, and capital-spending needs; the Q3 2022 runway estimate includes anticipated Pfizer proceeds.
- Monitor whether Novartis programs advance and whether any milestone or royalty payments become probable or are earned.